Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?

Abstract

The COVID-19 pandemic required urgency in the development and delivery of effective vaccines and therapeutics; meanwhile, ongoing clinical research, regulation and supply for other much-needed therapeutics and vaccines needed to be sustained. In Europe, the European Commission, the European Medicines Agency (EMA) and the national regulatory agencies (NRAs) responded by issuing guidance outlining regulatory flexibilities mainly directed at COVID-19 vaccines and, belatedly, therapeutics. Using a survey methodology, this study gathered the views of the R&D based pharmaceutical industry in May–June 2021 on the value of these flexibilities for continued use in the post-pandemic era as well as for future use in health emergency situations. Findings indicate that many flexibilities were foreseen to have value beyond the pandemic, particularly where EU and Member States aligned closely to provide a singular, streamlined regulatory environment. Digitalization was a notable driver of these flexibilities, but innovations in regulatory process (e.g. rolling reviews, flexible Scientific Advice) improved the process and outcomes measurably. Finally, the rapid reaction of the EU regulatory system and extensive efforts by all involved in providing innovative therapeutics and vaccines to patients in need provides learnings for the upcoming overhaul of the pharmaceutical acquis. Supplementary Information The online version contains supplementary material available at 10.1007/s43441-022-00383-3.

Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study

“…There have been numerous publications addressing which of the agilities applied during the pandemic could be carried forward as standard practice (1,4,10,12,25,(40)(41)(42). In the opinion of the authors, this study makes a strong case for carrying forward labeling agilities.…”

Regulatory approval pathway for COVID-19 vaccine in USA, Europe and India

“…A marketing permission holder may be needed to undertake safety data studies as part of the authorization process; however, this is not always the case. Immunization programmes themselves will do additional research in this area 12 .…”

Analysis of COVID-19 diagnostic test implementation in Brazil: strategies in place at the beginning of the pandemic

“…Since the beginning of the COVID-19 pandemic, the World Health Organization (WHO) has recom-mended the mass testing as main strategy to controlling the spread of the new coronavirus, especially since there were still no approved vaccines against the disease (OMS, 2020b). Consequently, several regulatory agencies have adopted a posture of flexibility in their rules considering different critical items in the emergency moment, including applications for registration of in vitro diagnostic kits (Bolislis et al, 2021;Klein et al, 2022). Thus, WHO's recommendation was effi-ciently adopted in different countries, such as the Republic of Korea, Germany, among others (DEKA; KALITA, 2020;LEE;LEE, 2020).…”